Welcome!

News Feed Item

Next-Generation Biologics R&D, Industry and Market 2014-2024

LONDON, April 12, 2014 /PRNewswire/ --

Emerging biological drugs - discover R&D, business analysis, and revenue forecasts

What's the future of biologics, especially new drug classes? Now get the latest technological and commercial analysis. Staying ahead in data and knowledge, you benefit your authority. And you explore trends, developments, results, opportunities, and sales predictions.

So visiongain's new report shows you what's possible for biological drugs - their next phase. There avoid missing out. Instead find progress in that industry and market, discovering expected progress and revenues. See now how you can gain.

New biotechnological medicines will benefit patients and pharmaceutical companies. Read on to explore those therapies, hearing how high revenues can go.

Forecasting and other information showing the most lucrative possibilities for treatments
That study gives you sales forecasts to 2024 at overall world, submarket, product, and national level. See what the future holds, assessing gains for developers and producers.

Many opportunities exist. And besides giving revenue predictions, that new analysis shows recent results, growth rates, and market shares. There you discover 94 tables, 55 charts, and two interviews with authorities in the biopharmaceuticals sector.

And the following sections explain what our new investigation gives you.

Analyses exclusive to that study, showing the most important commercial potentials
In our report you get data found nowhere else. Discover what's really going on. Our forecasting system goes to the core of the biopharmaceutical industry's sales potential like no other work, giving revenue predictions and their meanings.

That analysis benefits your plans, decisions, and influence by interpreting medical needs, R&D, and companies' abilities. You hear what's happening, then, assessing likely gains.

So find in those analyses where potential and money lie, also saving time, worry, and effort.

Prospects for the world market and submarkets - what's possible for pharma biotechnology?
There, in our report, discover overall world sales to 2024 for biologics and new therapies, with discussions.

Also get individual revenue predictions to 2024 for 17 next-generation biologic submarkets at world level: 

• Regenerative medicine, with submarket breakdowns for tissue engineering, stem cells, and gene therapies
• Antibodies, including monoclonal antibodies (mAbs), with sub-forecasting for antibody-drug conjugates (ADCs), engineered, and bispecific agents
• Antibody fragments and antibody-like protein (ALP) platforms
• Biosimilars (follow-on protein products).

To see a report overview please email Sara Peerun on [email protected]

And discover other segments' forecasts to 2024: 

• Insulins, with submarkets for ultra-long acting, oral, and ultra-rapid-acting insulins
• Growth hormones
• Recombinant coagulation factors
• Other types of next-stage therapeutic proteins.

Next-generation biologics that treat new indications will be launched within 10 years. And you assess outlooks for that expansion in trade, hearing where you could gain.

Our study also explores competition. There you see what's happening for developers, producers, and sellers of new-generation biologics, understanding challenges, trends, and outlooks.

That work also splits its overall world market into leading products, showing where you could profit from new and improved biotech medicines.

Product forecasts for new forms, variations, and uses of biological therapy
How will individual drugs perform to 2024 at world level? Our report predicts revenues of seven top brands:

• Adcetris
• Kadcyla
• Gazyva
• Tresiba
• Afrezza
• Plegridy
• Eloctate.

There you find products and years with highest forecasted sales. And the report predicts those seven therapies will earn combined revenue of more than $10bn in 2024.

You also examine competitors. See what's happening, then, understanding challenges, trends, competition, and opportunities. And here's what that study's author said:

"Next-generation biologics will address shortcomings in current therapies, including inconvenient dosing and concerns over side effects. Developmental trends include sustained release, for less-frequent dosing, and reformulations for oral and topical administration."

That work also gives geographical revenue forecasts.

Healthcare in national markets - what outlooks for business in new biopharma products?
Advances in biotechnology and healthcare expand use of novel biological drugs in developed and developing countries. Also opportunities exist for newer treatments.

And our analyses show you individual revenue forecasts to 2024 for nine national markets: 

United States (US)
Japan
• EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
China
India.

There you hear about the best sales potentials, appraising national opportunities for next-generation biologicals. See where and how you can profit.

For treating people and saving lives, you explore progress, needs, and possibilities. Find how pharma companies satisfy those demands, also assessing expected financial gains.

And what events influence the biologics industry? What's the outlook for tackling serious diseases? Our work shows you, discussing trends, challenges, and opportunities.

Market forces and issues - what affects biopharma developers, producers, and sellers?
The report explains trends, processes, and events affecting the biopharma industry and market from 2014, including these forces:

• Limitations of existing biologics
• Promise of next-generation biologics, and product launches
• Extension of half-life - pegylation and other technologies
• Demand rising for biological therapies
• Contract manufacturers (CMOs) serving those developmental needs and trends.

To see a report overview please email Sara Peerun on [email protected]

And you explore these influences, among others: 

• Disease incidence affecting demand for those more-developed medicines
• Improvements in therapeutic antibodies, including targeted cytotoxic therapies
• R&D pipelines - e.g. for immunotoxins - including agents in clinical development
• Biosimilar insulins likely from 2015 - transformation of that market
• Effects of rising incidence rates in cancer, diabetes, and cardiovascular disorders.

There discover what the future holds. You explore political, economic, social, and technological questions. See too how R&D helps companies benefit patients.

So you explore what progress, trends, and prospects mean. And discover what helps and what hinders players in that healthcare industry, affecting participants' results.

Biological drug technology and applications - companies and 2018 market value
So what happens next? From 2014, novel and biosimilar treatments will benefit patients, doctors, and payers. Those advances will encourage investments, medical progress, and higher revenues from more-advanced biological drugs.

And our study predicts the next-generation biologics market will reach $12.17bn worldwide in 2018, and then multiply in revenues to 2024. See what's possible and what you can gain.

That work also explores activities of these leading companies, among many other firms: 

• Roche
• Eli Lilly
• Novo Nordisk
• Sanofi
• Pfizer
• Kyowa Hakko Kirin
• Baxter International.

In that market, large pharmaceutical corporations and smaller biopharma specialists can win. See how.

And you find 235 organisations covered. You also get interviews with two companies in the industry, helping you stay ahead. See, then, what the future holds.

Ways Next-Generation Biologics: R&D, Industry and Market 2014-2024 helps
In three main ways our new investigation helps you gain recognition for insight, with data found only there:

• Revenues to 2024 at world level, for 17 submarkets, and 7 products - explore outlooks for production, marketing, and sales
• Forecasts to 2024 for 9 national markets in North America, Europe, and Asia - assess countries for revenues and sales expansions
• Prospects for established competitors, rising companies, and new entrants - investigate portfolios, results, strategies, R&D, and opinions from interviews.

Knowledge there found nowhere else, helping your searches, analyses, and planning
Our new report provides competitive intelligence, showing where progress and money lie.

That work's purpose is to predict sales results with maximum clarity, applicability, and detail. And its research and analyses identify and explain commercial prospects. Now you explore the biological drug industry's future through data exclusive to that study.

So our analysis helps you avoid falling behind in information or missing opportunity. Also it lets you save time and effort. And now your choice could benefit your plans, decisions, and authority - increasing your chances of finding competitive advantages.

Biopharmaceutical knowledge - getting our new report now helps you stay ahead
By trying our new study on emerging biologicals you explore trends, R&D, and sales predictions. There stay ahead - please get that report here now.

To request a report overview please email Sara Peerun at [email protected] or call Tel : +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1235/Next-Generation-Biologics-R-D-Industry-and-Market-2014-2024

Companies Listed in this report: 

3SBio
Aastrom Biosciences
AbbVie
Abcam
Ablynx
ADC Therapeutics
Adnexus (part of Bristol-Myers Squibb)
Adocia
Advanced Cell Technology
Advantagene
Affibody
Agence Nationale de sécurité du Médicament et des produits de santé (ANSM)
Alcon (part of Novartis)
Alexion Pharmaceuticals
Alfacell (now Tamir Biotechnology)
Alkermes
Allergan
Allozyne
Ambrx
Amgen
AMRI
AnGes
Applied Genetic Technologies (AGTC)
Ark Therapeutics
Astellas Pharma
AstraZeneca
Athersys
Avita Medical
Babraham Institute
Baxter International
Bayer Healthcare
Belrose Pharma
Benda Pharmaceutical
Biocad
BioCancell Therapeutics
Biocon
Biodel
Biogen Idec
Bioheart
BioMarin Pharmaceutical
Biopartners (part of Bioton)
Biotest
Bioton
BioVex Group (part of Amgen)
BioWa (part of Kyowa Hakko Kirin)
bluebird bio
Boehringer Ingelheim
BrainStorm Cell Therapeutics
Bristol-Myers Squibb
Capricor Therapeutics
Cardio3 BioSciences
Cardium Therapeutics
Catalent Pharma Solutions
Celgene
Celladon
CellCoTec
Celldex Therapeutics
Cellerant Therapeutics
Cellular Dynamics International (CDI)
Centers for Disease Prevention and Control (CDC) [US]
Cephalon (part of Teva)
CEPiA (part of Sanofi)
Ceregene
Chatham Therapeutics
Chiesi Farmaceutici
Children's Hospital of Philadelphia (CHOP)
China Food and Drug Administration (CFDA)
Chugai (part of Roche)
Civitas Therapeutics
Clayton Biotechnologies
Cold Genesys
Concortis
Covagen
Crescendo Biologics
Critical Pharmaceuticals
CSL Behring
CytoMedix
Cytori Therapeutics
Dance Biopharm
Delenex Therapeutics
Depuy Mitek (part of J&J)
Diabetology
Dr. Reddy's Laboratories
Duke University
Duke University Hospital
Dyax
Eddingpharm
EGEN
Eisai
Elan Pharmaceuticals (now part of Perrigo Company)
Eli Lilly
EMA's Committee for Medicinal Products for Human Use (CHMP)
Emisphere
Enzon Pharmaceuticals
EnzymeRx
Epitomics (part of Abcam)
ESBATech (part of Novartis)
European Commission
European Medicines Agency (EMA)
Flamel Technologies
Food and Drug Administration (FDA) [US]
Fresenius Biotech (now named Neovii Biotech, part of Neopharm)
Fuji Pharma
Fujifilm Diosynth Biotechnologies
Gamida Cell
Genentech (part of Roche)
Generex Biotechnology
Genzyme (part of Sanofi)
Geron
GlycoExpress
Glycotope
GSK
Halozyme Therapeutics
Hanmi Pharmaceutical
Health Canada
Hikma Pharmaceuticals
Histogenics
Humacyte
Human Stem Cells Institute (HSCI)
Igenica
ImmunoGen
Immunomedics
Innovent Biologics
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Germany]
Integra LifeSciences
International Diabetes Federation (IDF)
Introgen Therapeutics
J&J
Jain Foundation
JCR Pharmaceuticals
Juventas Therapeutics
Karolinska Institute
Kyowa Hakko Kirin
LG Life Sciences
LifeCell
Lonza
MacroGenics
MannKind
MedImmune (part of AstraZeneca)
Merck & Co.
Merck KGaA
Merrimack Pharmaceuticals
Merrion Pharmaceuticals
Mersana Therapeutics
Mesoblast
Micromet (part of Amgen)
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Mitsubishi Tanabe Pharma
Mochida Pharmaceutical
Molecular Partners
Moorfields Eye Hospital [UK]
MorphoSys
National Cancer Institute (NCI) [US]
National Health Service (NHS) [UK]
National Institute for Health and Care Excellence (NICE) [UK]
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [US]
Neopharm Group
NeoStem
NeuralStem
Nippon Kayaku
Novartis
Novo Nordisk
Nuron Biotech
NuVasive
OncoSec Medical
OPKO Health
Oramed Pharmaceuticals
Organogenesis
Organovo
Orthofix
Osiris Therapeutics
PeriphaGen Holdings
Perrigo Company
Pfizer
Pieris
Piramal Group
Progenics Pharmaceuticals
Prolor Biotech (part of OPKO Health)
Rani Therapeutics
ratiopharm (part of Teva)
Redwood Bioscience
Regeneron Pharmaceuticals
Reliance Life Sciences
ReNeuron
RIKEN [Japan]
Roche
Roche Glycart (part of Roche)
Royal Institute of Technology [Sweden]
Russian Ministry of Healthcare (Minzdrav)
SAFC
Sandoz (part of Novartis)
Sanofi
Scottish Medicines Consortium (SMC)
Seattle Genetics
Shanghai Sunway Biotech
Shenzhen SiBiono GeneTech (part of Benda)
Shreya Life Sciences
SironRX Therapeutics
Skye Orthobiologics
Sorrento Therapeutics
Sotex PharmFirm
Spark Therapeutics
Spectrum Pharmaceuticals
Spirogen (part of AstraZeneca)
Stanford University
Stelis Biopharmaceuticals (part of Strides Arcolab)
StemCells
Stempeutics Research
Strativa Pharmaceuticals
Strides Arcolab
Sutro Biopharma
Swedish Orphan Biovitrum (Sobi)
Swiss Federal Institute of Technology
Symphogen
Synthon
Synthon Biopharmaceuticals (part of Synthon)
Takeda Pharmaceutical Company
Teva Pharmaceutical Industries
Thermalin Diabetes
Tianjin International Joint Academy of Bio-medicine
TiGenix
University of Toronto
TRION Pharma
UCB
University of California, San Francisco (UCSF)
UniQure
USV
VBL Therapeutics
Versartis
viDA Therapeutics
VX Pharma
World Bank Group
World Cancer Research Fund (WCRF)
World Health Organization (WHO)
Wyeth (part of Pfizer)
Xencor
Xeris Pharmaceuticals
Yale School of Medicine
Zydus Cadila

To see a report overview please email Sara Peerun on [email protected]

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Join IBM November 1 at 21st Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA, and learn how IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Cognitive analysis impacts today’s systems with unparalleled ability that were previously available only to manned, back-end operations. Thanks to cloud processing, IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Imagine a robot vacuum that becomes your personal assistant tha...
Cloud Expo, Inc. has announced today that Andi Mann and Aruna Ravichandran have been named Co-Chairs of @DevOpsSummit at Cloud Expo Silicon Valley which will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. "DevOps is at the intersection of technology and business-optimizing tools, organizations and processes to bring measurable improvements in productivity and profitability," said Aruna Ravichandran, vice president, DevOps product and solutions marketing...
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous a...
SYS-CON Events announced today that IBM has been named “Diamond Sponsor” of SYS-CON's 21st Cloud Expo, which will take place on October 31 through November 2nd 2017 at the Santa Clara Convention Center in Santa Clara, California.
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, will lead you through the exciting evolution of the cloud. He'll look at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering ...
SYS-CON Events announced today that N3N will exhibit at SYS-CON's @ThingsExpo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. N3N’s solutions increase the effectiveness of operations and control centers, increase the value of IoT investments, and facilitate real-time operational decision making. N3N enables operations teams with a four dimensional digital “big board” that consolidates real-time live video feeds alongside IoT sensor data a...
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It’s clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. Tha...
SYS-CON Events announced today that Avere Systems, a leading provider of enterprise storage for the hybrid cloud, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Avere delivers a more modern architectural approach to storage that doesn't require the overprovisioning of storage capacity to achieve performance, overspending on expensive storage media for inactive data or the overbui...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend 21st Cloud Expo October 31 - November 2, 2017, at the Santa Clara Convention Center, CA, and June 12-14, 2018, at the Javits Center in New York City, NY, and learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
We all know that end users experience the Internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices – not doing so will be a path to eventual b...
The dynamic nature of the cloud means that change is a constant when it comes to modern cloud-based infrastructure. Delivering modern applications to end users, therefore, is a constantly shifting challenge. Delivery automation helps IT Ops teams ensure that apps are providing an optimal end user experience over hybrid-cloud and multi-cloud environments, no matter what the current state of the infrastructure is. To employ a delivery automation strategy that reflects your business rules, making r...
Digital transformation is changing the face of business. The IDC predicts that enterprises will commit to a massive new scale of digital transformation, to stake out leadership positions in the "digital transformation economy." Accordingly, attendees at the upcoming Cloud Expo | @ThingsExpo at the Santa Clara Convention Center in Santa Clara, CA, Oct 31-Nov 2, will find fresh new content in a new track called Enterprise Cloud & Digital Transformation.
Most technology leaders, contemporary and from the hardware era, are reshaping their businesses to do software. They hope to capture value from emerging technologies such as IoT, SDN, and AI. Ultimately, irrespective of the vertical, it is about deriving value from independent software applications participating in an ecosystem as one comprehensive solution. In his session at @ThingsExpo, Kausik Sridhar, founder and CTO of Pulzze Systems, will discuss how given the magnitude of today's applicati...